In the rapidly evolving landscape of cardiovascular medicine, the treatment of aortic valve disease has become a flashpoint for clinical philosophy, institutional politics, and patient-centered decision-making. A new analysis of registry data has injected fresh evidence into the ongoing debate over the use of transcatheter aortic valve implantation (TAVI) in patients younger than 65. While some experts view the data as a validation of the "Heart Team" model, others remain deeply skeptical, arguing that the persistent use of TAVI in this demographic violates established guidelines and risks long-term harm.
The Core Conflict: Guidelines vs. Clinical Reality
Current US and European guidelines for valvular heart disease generally recommend surgical aortic valve replacement (SAVR) over TAVI for patients younger than 65. This clinical stance is predicated on a straightforward reality: the long-term durability of transcatheter valves in younger, more active patients remains unproven. Despite these recommendations, observational studies have periodically suggested that TAVI utilization rates in this younger cohort have reached as high as 50% in certain regions, sparking intense concern regarding "risk creep" and "age creep"—the tendency to offer less-invasive procedures to patients who may not strictly fit the original criteria for TAVI.
The latest study, published in Circulation: Cardiovascular Interventions, utilized data from the Vizient Clinical Database to track 34,504 patients under the age of 65 who underwent aortic valve replacement between 2016 and 2024. The findings reveal a more complex picture than previous, more alarming reports suggested. Approximately 28.5% of the studied cohort received TAVI, while the remainder underwent various forms of surgery, including isolated SAVR (31.8%), concomitant SAVR (37.8%), and the Ross procedure (1.9%).
Chronology of the TAVI Shift (2016–2024)
The trajectory of TAVI adoption over the past decade reflects both the rapid technological advancement of the procedure and a subsequent period of clinical reflection.
- 2016–2020: The Exponential Growth Phase. During the first half of the study period, the prevalence of TAVI in patients under 65 grew steadily. The proportion of these patients receiving TAVI doubled from 15.7% in 2016 to a peak of 36.8% by 2020. This shift mirrored a corresponding decline in the rates of isolated SAVR, which dropped from 43.8% to 27.4% over the same timeframe.
- 2020–2024: The Plateau. Following 2020, the trend shifted significantly. The rapid expansion of TAVI in younger patients stagnated, and in some metrics, began to reverse. By 2024, the rates of TAVI and isolated SAVR had reached a period of relative stability, suggesting that the clinical community may have reached a consensus or a "natural equilibrium" regarding the appropriate patient selection for TAVI.
- Consistent Surgical Foundations. Throughout this entire period, the rate of concomitant SAVR—surgeries where the aortic valve is replaced alongside other procedures like coronary artery bypass grafting (CABG) or ascending aorta repair—remained remarkably stable, hovering between 34% and 40%. Additionally, the use of mechanical valves remained steady, indicating that surgical options remain a robust pillar of care.
Data Breakdown: A Closer Look at the Cohort
The Vizient data offers a unique vantage point by including not just "clean" cases of isolated aortic stenosis, but also the more complicated patients often seen in real-world clinical practice.
Senior author Dr. Harold Dauerman of the University of Vermont Medical Center notes that the data highlights the prevalence of comorbidities. "What’s interesting from this paper is how many patients don’t just have isolated aortic stenosis," Dr. Dauerman observed. "They have ascending aortas that are dilated, or they need a CABG, or they need their mitral valve fixed. When you add those patients, and you add in patients getting mechanical valves and the Ross procedure, you see this big chunk—nearly 40%—that are clearly surgical."
The data also points to a resurgence of the Ross procedure—a complex, highly skilled surgery often reserved for younger, low-risk patients. Growing from a mere 0.4% in 2016 to 4.8% in 2024, this trend is being hailed by some experts as a positive sign that younger, healthier patients are being steered toward more durable, albeit surgically intensive, options.
Official Responses and Professional Perspectives
The interpretation of this data remains starkly divided among leaders in the field.
The Optimists: The Heart Team is Working
Dr. Molly Szerlip of Baylor Scott and White, The Heart Hospital, argues that the narrative of "TAVI gone wild" is misplaced. Having previously conducted research that characterized younger TAVI recipients as being sicker and having fewer alternatives, she believes that the Heart Team—the collaborative group of interventional cardiologists and cardiac surgeons—is functioning as intended.
"People keep saying that younger patients are getting the wrong treatment, and I am just not seeing that," Dr. Szerlip said. "I think right now the correct patients are getting the correct technology." She emphasizes that the Heart Team is "alive and well" in institutions where there is genuine collaboration, and she warns against policies that might sideline surgeons, which she believes would be a "travesty" for patient care.
The Skeptics: A Continued Cause for Alarm
Conversely, Dr. Tsuyoshi Kaneko of the Washington University School of Medicine remains unconvinced by the "reassuring" nature of the data. Dr. Kaneko argues that a 29% TAVI rate for patients under 65 is still far too high, given that there is no robust randomized control trial evidence to support TAVI over SAVR in this demographic.
"The age creep and the risk creep in this group is very concerning," Dr. Kaneko stated. He pointed out that the study lacks granular detail on bicuspid anatomy and specific risk profiles, which are critical factors in deciding between surgery and TAVI. He posits that the stagnation of TAVI growth observed after 2020 might not be a sign of a "functioning Heart Team," but rather a reaction to the publication of early, grim data regarding TAVI explant outcomes.
Implications for Future Guidelines and Practice
As the cardiovascular community awaits the next iteration of the US valvular heart disease guidelines, expected in 2026, the stakes for patient care are high.
Preservation of Clinical Judgment
Dr. Dauerman advocates for a more nuanced approach in future guidelines. While acknowledging that age cutoffs are useful, he hopes to see a greater emphasis on anatomical and clinical risk factors. He warns against a rigid, binary system that ignores the reality of patients with severe comorbidities or complex anatomical needs who might be poor candidates for open-heart surgery, regardless of their age.
The Continued Role of the Age Cutoff
Most experts, including Dr. Kaneko, believe that the 65-year-old threshold is likely to remain in the upcoming guidelines. "I do not foresee a guideline without an age cutoff," Dr. Kaneko remarked, noting the lack of strong clinical evidence to justify lowering the age for TAVI in the absence of significant surgical contraindications.
Clinical Research as the Final Arbiter
The ongoing debate highlights the necessity for rigorous, prospective data. Trials such as the NAVIGATE Bicuspid and BELIEVERS studies are expected to shed light on how specific populations—particularly those with bicuspid valves—fare with transcatheter technologies.
Ultimately, the goal remains the same: the delivery of the best possible care for patients facing a lifetime of valve management. Whether the Heart Team is currently succeeding in this mission or struggling under the pressure of new technology remains the defining question of the decade. As Dr. Szerlip aptly put it, "I think patients get the best care when the surgeons and the cardiologists are in a unified front making sure that the right people are getting the right treatment." The challenge for the next several years will be defining exactly who those "right" people are, supported by data rather than the "tones of fear, power, and control" that have characterized much of the recent discourse.
